$ELAN

Kurzius Lawrence Erik purchased $936K of ELAN

Kurzius Lawrence Erik purchased 40,000 shares of Elanco Animal Health Inc (ELAN) at $23.40 ($0.94M total) on 2026-08-20.

Original reporting
SEC EDGAR · Kurzius Lawrence Erik
Published Aug 21, 2026, 8:16 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 21, 2026, 8:41 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$ELAN
Bullish
medium confidence
Mentioned
$ELAN
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ELANBullishLow
01

Why it matters

The disclosed purchase adds a new data point on insider sentiment for ELAN.

02

Market read

A director's $0.94M share purchase may influence short‑term sentiment but is unlikely to move the stock dramatically.

03

What to watch

No pre‑arranged 10b5‑1 plan; purchase may reflect personal financial planning.

Relevance 6/10Novelty 7/10Timing: post‑market filing on Aug 21, 2026

Background

Form 4 filings disclose insider transactions; director purchases are monitored for potential signals.

Company-level read

Ticker impact

$ELANBullishMedium confidence
Context

Director Lawrence Erik Kurzius purchased 40,000 shares for $935,920, increasing his holding to 188,647 shares.

Expected impact

Potential modest upside as market digests insider support.

Evidence & confidence

The purchase size (~$0.94M) is notable for a director but below materiality thresholds that drive large price moves.

Market effects

May be viewed positively by animal health sector investors.

Limited to US equity markets where ELAN trades.

Low global impact.

Counterpoint

Insider buying could be routine portfolio rebalancing, not a strong bullish signal.

Key entities

  • Elanco Animal Health Inc

    US‑listed animal health products manufacturer (ticker ELAN).

  • Lawrence Erik Kurzius

    Director of ELAN who made the purchase.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ELANMed

Elanco rating upgraded by Fitch on deleveraging progress

Fitch Ratings upgraded Elanco Animal Health’s (NYSE:ELAN) Long-Term Issuer Default Rating to BB+ from BB and raised senior secured to BBB- from BB+ and senior unsecured to BB+ from BB, with a stable outlook. Fitch cited balance-sheet deleveraging, share gains, and cash flow. It projects EBITDA leverage below 3.5x, debt down about $650M since 2024, and free cash flow rising from $345M (2026) to ~$575M (2028).

$ELANHighAI 9/10

Elanco (ELAN) Q2 2026 Earnings Call Transcript

Elanco Animal Health (ELAN) reported Q2 2026 revenue of $1.368B, up 8% organic constant currency, and adjusted EBITDA of $288M (+21%). Adjusted EPS was $0.34 (+31%). Management raised 2026 revenue guidance to $5.09B-$5.14B and adjusted EPS to $1.10-$1.16, citing innovation sales led by Zenrelia and Credelio Quattro.

$ELANHighAI 8/10

ELAN Stock Jumps As Earnings Beat Fuels Bullish Guidance

Elanco Animal Health (NYSE: ELAN) shares rose about 3.4% after Q2 2026 results beat expectations and management raised guidance. Elanco reported revenue of $1.37B vs $1.31B expected and adjusted EPS of $0.34 vs $0.27, with 2026 guidance of EPS $1.10–$1.16 and revenue $5.09B–$5.14B. Analysts including KeyBanc, UBS and Citi raised targets to $30–$34.

$ELANMedAI 8/10

Elanco Animal Health Q2 Earnings Call Highlights

Elanco Animal Health (NYSE:ELAN) reported Q2 updates on pet and farm results. Credelio Quattro gained market share, with product in over half of U.S. clinics. Early Befrena demand was described as soft-launched in May, with supply constrained until early 2027. AdTab international OTC parasiticides sales rose over 30%. Elanco raised 2026 innovation revenue target to about $1.25B and guided FY revenue $5.09B-$5.14B, adjusted EBITDA $1.01B-$1.035B, adjusted EPS $1.10-$1.16.

$ELANMedAI 8/10

Elanco Animal Health Boosts FY26 Outlook; Stock Up 7% - Update

Elanco Animal Health (ELAN) reported Q2 results and issued Q3 guidance, expecting adjusted EPS of $0.19 to $0.22 on revenue of $1.195B to $1.220B, with 5% to 7% organic constant-currency growth. For FY2026, it raised outlook to adjusted EPS $1.10 to $1.16 on revenue $5.09B to $5.14B, up from prior $1.03 to $1.09 on $5.01B to $5.085B. Shares rose to $27.37.